Company Filing History:
Years Active: 2001-2010
Title: Marcel Behr: Innovator in Mycobacterial Research
Introduction
Marcel Behr is a prominent inventor based in Montreal, Canada. He has made significant contributions to the field of mycobacterial research, particularly in understanding genetic deletions in mycobacteria isolates. With a total of 4 patents, his work has implications for tuberculosis diagnosis and vaccine efficacy.
Latest Patents
Behr's latest patents focus on identifying specific genetic deletions in mycobacteria isolates. These deletions serve as markers to distinguish between pathogenic and avirulent strains. His research highlights variations in the genome sequence between isolates, including numerous deletions present in BCG compared to Mycobacterium tuberculosis (M. tb). These findings are crucial for determining whether a positive tuberculin skin test indicates actual tuberculosis infection. Furthermore, the deleted sequences may be reintroduced into BCG to enhance vaccination efficacy. Alternatively, the genetic sequences corresponding to these deletions can be removed to attenuate pathogenic bacteria.
Career Highlights
Marcel Behr is affiliated with Leland Stanford Junior University, where he continues to advance research in mycobacterial genetics. His innovative work has garnered attention in the scientific community, contributing to a better understanding of tuberculosis and its treatment.
Collaborations
Throughout his career, Behr has collaborated with notable colleagues, including Peter Small and Gary K. Schoolnik. These partnerships have further enriched his research and expanded the impact of his findings.
Conclusion
Marcel Behr's contributions to mycobacterial research and his innovative patents play a vital role in advancing our understanding of tuberculosis. His work not only aids in distinguishing between different strains but also enhances the efficacy of vaccines, making a significant impact in the field of infectious diseases.